Featured Research

from universities, journals, and other organizations

Cancer patients with blood clots gain no benefit from adding IVCF to fondaparinux

Date:
July 7, 2011
Source:
International Association for the Study of Lung Cancer
Summary:
Cancer patients with blood clots -- which occur in one of every 200 cancer patients and are the second most common cause of death among cancer patients -- gain no benefit from the insertion of an inferior vena cava filter (IVCF) to the anticoagulant medication fondaparinux (Arixtra), according to new research.

Cancer patients with blood clots -- which occur in one of every 200 cancer patients and are the second most common cause of death among cancer patients -- gain no benefit from the insertion of an inferior vena cava filter (IVCF) to the anticoagulant medication fondaparinux (Arixtra), according to research presented July 7 at the 14th World Conference on Lung Cancer, hosted by the International Association for the Study of Lung Cancer.

"This is the first prospective study to evaluate the treatment of venous thromboembolism (VTE) or blood clots in cancer patients and is a potentially practice-changing clinical trial," said principal investigator Dr. Myra Barginear, M.D., of The North Shore-LIJ Health System in New York, U.S.A. The inferior vena cava is a large blood vessel in the abdomen that carries blood from the lower parts of the body back to the heart. A thin-mesh IVC filter can be placed in the inferior vena cava to prevent blood clots, or VTEs, from reaching the heart.

In the study, sixty-four patients with deep venous thrombosis (86%) and/or pulmonary embolism (55%) received fondaparinux. About half of patients received only fondaparinux, while the other half received fondaparinux in conjunction with an IVCF.

The median survival for patients receiving only fondaparinux was 493 days, compared with 266 days for patients on fondaparinux plus an IVCF. Meanwhile, a median 52% of patients on fondaparinux alone experienced a complete resolution of VTEs, compared with 45% of patients on fondaparinux plus IVCF.

The study suggests that there is no benefit from costly and invasive IVCF placement in patients who are receiving fondaparinux. The results also support future randomized trials to compare VTE resolution rates achieved with fondaparinux with low molecular weight heparin, another class of anticoagulant medication.


Story Source:

The above story is based on materials provided by International Association for the Study of Lung Cancer. Note: Materials may be edited for content and length.


Cite This Page:

International Association for the Study of Lung Cancer. "Cancer patients with blood clots gain no benefit from adding IVCF to fondaparinux." ScienceDaily. ScienceDaily, 7 July 2011. <www.sciencedaily.com/releases/2011/07/110707081946.htm>.
International Association for the Study of Lung Cancer. (2011, July 7). Cancer patients with blood clots gain no benefit from adding IVCF to fondaparinux. ScienceDaily. Retrieved October 1, 2014 from www.sciencedaily.com/releases/2011/07/110707081946.htm
International Association for the Study of Lung Cancer. "Cancer patients with blood clots gain no benefit from adding IVCF to fondaparinux." ScienceDaily. www.sciencedaily.com/releases/2011/07/110707081946.htm (accessed October 1, 2014).

Share This



More Health & Medicine News

Wednesday, October 1, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Ebola Cases Keep Coming for Monrovia's Island Hospital

Ebola Cases Keep Coming for Monrovia's Island Hospital

AFP (Oct. 1, 2014) A look inside Monrovia's Island Hospital, a key treatment centre in the fight against Ebola in Liberia's capital city. Duration: 00:34 Video provided by AFP
Powered by NewsLook.com
Ebola Puts Stress on Liberian Health Workers

Ebola Puts Stress on Liberian Health Workers

AP (Oct. 1, 2014) The Ebola outbreak is putting stress on first responders in Liberia. Ambulance drivers say they are struggling with chronic shortages of safety equipment and patients who don't want to go to the hospital. (Oct. 1) Video provided by AP
Powered by NewsLook.com
Doctors Reassure Public Ebola Patient Won't Cause Outbreak

Doctors Reassure Public Ebola Patient Won't Cause Outbreak

Newsy (Sep. 30, 2014) After the announcement that the first U.S. patient had been diagnosed with Ebola, doctors were quick to say a U.S. outbreak is highly unlikely. Video provided by Newsy
Powered by NewsLook.com
TX Hospital Confirms Patient Admitted With Ebola

TX Hospital Confirms Patient Admitted With Ebola

AP (Sep. 30, 2014) Medical officials from Texas Health Presbyterian Hospital confirm they are treating a patient with the Ebola virus, the first case found in the US. (Sept. 30 Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins